多潘立酮对肝硬化患者门脉系统血流量的影响

Effect of Domperidone on the Blood Flow of Portal Venous System in Patients with Liver Cirrhosis

背景:肝硬化病程迁延且内外科治疗效果均不理想,寻找有效的治疗药物一直是该领域研究的热点。目的:探讨多潘立酮对肝硬化患者门脉系统血流量的影响。方法:以20名健康人作为正常对照,用多普勒超声分别测定32例肝硬化患者服用多潘立酮前和服用2周后的门静脉、脾静脉和肠系膜上静脉血流参数。多潘立酮的用法为10mg tid口服。结果:多潘立酮治疗前,肝硬化患者的门静脉血流量(PVF)显著低于正常对照组(P<0.01),脾静脉血流量(SVF)和肠系膜上静脉血流量(SMVF)显著高于正常对照组(p<0.01);治疗后,肝硬化患者的PVF较治疗前无显著差异,SVF和SMVF虽显著低于治疗前(P<0.01),但仍高于正常对照组(P<0.05)。结论:多潘立酮可能对肝硬化患者的内脏高动力循环状态有改善作用。

Background: Liver cirrhosis runs a chronic course, the therapeutic results of either medical or surgical are unsatisfactory, and searching for more effective drug is always the focus in this field. Aims: To study the effect of domperidone on the blood flow of portal venous system in patients with liver cirrhosis. Methods: Parameters of portal venous flow (PVF), splenic venous flow (SVF) and superior mesenteric venous flow (SMVF) were determined by Doppler ultrasonography in 32 patients with liver cirrhosis before and after oral administration of domperidone 10 mg tid for 2 weeks. Twenty healthy subjects served as normal controls. Results: Before treatment with domperidone, PVF in patients with cirrhotics was much lower than that in normal controls (P<0.01), and SVF and SMVF were greater than those in normal controls (P<0.01). No significant difference was found between PVF in cirrhotics before and after treatment, while SVF and SMVF in cirrhotics after treatment became lower than those before treatment (P<0.01), but still greater than those in normal controls (P<0.05). Conclusions: Domperidone may improve the visceral hyperkinetic circulatory status in patients with liver cirrhosis.